Author

Erin Conlin

Observed institutions: Bristol-Myers Squibb (United States), Celgene (United States)

OpenAlex ID: A5021680830

Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

2021 · Jason Fangusaro, Maria Giuseppina Cefalo, et al. · Frontiers in Oncology · 12

A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors.

2019 · Jason R. Fangusaro, Franco Locatelli, et al. · Journal of Clinical Oncology · 6

Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).

2016 · Grzegorz S. Nowakowski, Annalisa Chiappella, et al. · Journal of Clinical Oncology · 2

Abstract PO3-20-04: A first-in-human study of the highly selective PI3Kα inhibitor RLY-5836 in patients with advanced breast cancer and other solid tumors

2024 · Andreas Varkaris, Steven Isakoff, et al. · Cancer Research

A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia

2022 · Akshay Sharma, John P Manis, et al. · Blood

Works count: 5

Citation count: 20

H-index: 2

I10-index: 1